Sugi Predict

Sugi Predict / Compounds / SCHEMBL16513630

SCHEMBL16513630

SCHEMBL16513630

CN1CCN(c2ccc(Nc3ncc4cccc(-c5cccc(N)c5)c4n3)cn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 3/20 0.56
▸ BRD4 O60885 2/20 0.56
▸ EGFR P00533 2/20 0.52
▸ CTSC P53634 1/20 0.50
▸ FGFR1 P11362 2/20 0.49
▸ KDR P35968 1/20 0.49
▸ MAP3K7 O43318 1/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.48
▸ WEE1 P30291 1/20 0.45
▸ FGFR2 P21802 1/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ MAPK10 P53779 2/20 0.44
▸ MAP4K1 Q92918 1/20 0.43
▸ TTK P33981 2/20 0.42
▸ MET P08581 1/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ CDK4 P11802 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29847837 1.00 JAK2 (0.56) JAK2BRD4EGFRCTSCFGFR1
SCHEMBL16514469 0.89 WEE1 (0.48) JAK2BRD4EGFRWEE1FGFR2
SCHEMBL16514276 0.89 MAPK10 (0.54) JAK2BRD4EGFRMAP3K7IRAK4
SCHEMBL29848219 0.89 WEE1 (0.48) JAK2BRD4EGFRWEE1FGFR2
SCHEMBL29846917 0.89 JAK2 (0.70) JAK2BRD4EGFRFGFR1KDR
SCHEMBL16514362 0.89 JAK2 (0.70) JAK2BRD4EGFRFGFR1KDR
SCHEMBL16515375 0.87 CTSC (0.49) JAK2BRD4EGFRCTSCFGFR1
SCHEMBL29847583 0.87 CTSC (0.49) JAK2BRD4EGFRCTSCFGFR1
SCHEMBL16514104 0.85 EGFR (0.60) JAK2BRD4EGFRCTSCFGFR1
SCHEMBL29847622 0.85 EGFR (0.60) JAK2BRD4EGFRCTSCFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105682661-B Certain chemical entities, compositions, and methods 润新生物公司 2020-03-27 — — CN claimed
US-9849139-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-12-26 — — US claimed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US claimed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US claimed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP claimed
CN-105682661-A Certain chemical entities, compositions, and methods 润新生物公司 2016-06-15 — — CN claimed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US claimed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2022-11-10 — — US disclosed
CN-109851617-B Chemical entities, compositions, and methods 润新生物公司 2022-08-16 — — CN disclosed
US-20170050936-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2017-02-23 — — US disclosed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US disclosed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP disclosed
CN-105682661-A Certain chemical entities, compositions, and methods 润新生物公司 2016-06-15 — — CN disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JAK2 356/4885BRD4 474/4885EGFR 518/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JAK2 356/4885BRD4 474/4885EGFR 518/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 JAK2 356/4885BRD4 474/4885EGFR 518/4885
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 JAK2 53/4885BRD4 658/4885EGFR 272/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 JAK2 356/4885BRD4 474/4885EGFR 518/4885
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 JAK2 356/4885BRD4 474/4885EGFR 518/4885
US-20170050936-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CDK2, MAP3K6, MAP3K2 JAK2 248/4885BRD4 564/4885EGFR 555/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 JAK2 155/4885BRD4 1922/4885EGFR 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.